Quarterly ResultMay 6, 2026, 07:57 AM
Novo Nordisk Raises 2026 Outlook; Wegovy® Pill Drives Strong Q1
AI Summary
Novo Nordisk reported Q1 2026 adjusted sales of DKK 70,063 million, a 4% decrease at CER, and adjusted operating profit of DKK 32,858 million, a 6% decrease at CER. These figures exclude a USD 4.2 billion provision reversal related to the 340B Drug Pricing Program. The company's Obesity care sales grew by 22% at CER, significantly driven by the strong launch of Wegovy® pill in the US, which achieved DKK 2,256 million in Q1 sales and over 2 million prescriptions since January. Based on strong GLP-1 product sales, Novo Nordisk has raised its 2026 adjusted sales and operating profit growth outlook to -4% to -12% at CER.
Key Highlights
- Raised 2026 adjusted sales growth outlook to -4% to -12% at CER.
- Raised 2026 adjusted operating profit growth outlook to -4% to -12% at CER.
- Q1 2026 adjusted sales decreased 4% at CER to DKK 70,063 million.
- Q1 2026 adjusted operating profit decreased 6% at CER to DKK 32,858 million.
- Q1 2026 adjusted Obesity care sales grew 22% at CER to DKK 20,912 million.
- Wegovy® pill Q1 2026 sales reached DKK 2,256 million; over 2 million prescriptions since launch.
- Wegovy® HD (7.2 mg injectable) FDA approved in March, launched in US April 7.
- Awiqli® (once-weekly basal insulin) FDA approved for type 2 diabetes.